Adalimumab biosimilar is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF)，was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab biosimilar is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. 

Adalimumab biosimilar is supplied at a concentration of 50 mg/mL as a sterile, clear and colorless, preservative-free solution, which contains 1.3 mg/mL citric acid monohydrate, 1.525 mg/mL dibasic sodium phosphate dihydrate, 12 mg/mL mannitol, 0.8625 mg/mL monobasic sodium phosphate dihydrate, 1 mg/mL polysorbate 80, 6.1625 mg/mL sodium chloride, 0.3 mg/mL sodium citrate and Water for Injection.

Statement: this product is used for R&D only, not for clinical usage.

Name	Adalimumab Biosimilar
CAS NO.	331731-18-1
Type	Whole antibody
Source	Human
Target	TNF alpha
Clone	Monoclone
Formula	C6428H9912N1694O1987S46
Molecular Weight	148 kDa
Antibody Form	Purified immunoglobulin
Physical Form	Solution
Grade Standard	Medicine Grade
Storage	-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.

Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of Pharmaceutical Intermediates, APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc..

Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories.

Topwell aims to become a global leader in pharmaceutical & chemical industry.